- Home
- GNTX vs KNSA Comparison
GNTX vs KNSA Comparison
Compare GNTX & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTX | KNSA |
|---|---|---|
| Founded | 1974 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.9B |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GNTX | KNSA |
|---|---|---|
| Price | $21.11 | $79.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $27.28 | ★ $98.00 |
| AVG Volume (30 Days) | ★ 2.0M | 408.7K |
| Earning Date | 10-23-2026 | 10-27-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | ★ 1.00 | 0.27 |
| Revenue | ★ $2,534,268,965.00 | $677,564,000.00 |
| Revenue This Year | $5.41 | $46.66 |
| Revenue Next Year | $5.11 | $22.90 |
| P/E Ratio | ★ $21.15 | $291.67 |
| Revenue Growth | 9.55 | ★ 60.09 |
| 52 Week Low | $20.48 | $35.53 |
| 52 Week High | $26.96 | $82.94 |
Technical Indicators
Market Signals| Indicator | GNTX | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 32.24 | 60.46 |
| Support Level | $20.48 | $73.81 |
| Resistance Level | $22.37 | $81.42 |
| Average True Range (ATR) | 0.41 | 2.60 |
| MACD | -0.07 | 0.30 |
| Stochastic Oscillator | 17.42 | 86.28 |
Price Performance
Historical ComparisonAbout GNTX Gentex Corporation
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion, with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.